These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37591211)

  • 21. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
    Shu Y; Chen J; Ding Y; Zhang Q
    Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study.
    Ohe Y; Yamazaki N; Yamamoto N; Murakami H; Yoh K; Kitano S; Hashimoto H; Murayama A; Nakane S; Gemma A
    Jpn J Clin Oncol; 2022 May; 52(6):623-632. PubMed ID: 35325169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database.
    Sato J; Uchida M; Wakabayashi H; Shimizu T
    Anticancer Res; 2022 Jun; 42(6):3109-3116. PubMed ID: 35641286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
    Garon EB; Aerts J; Kim JS; Muehlenbein CE; Peterson P; Rizzo MT; Gadgeel SM
    Lung Cancer; 2021 May; 155():53-60. PubMed ID: 33730652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of drug-induced interstitial lung disease caused by herbal medicine using the Japanese Adverse Drug Event Report database.
    Oura K; Tanaka M; Matsumoto K; Satake R; Inoue M; Yoshida Y; Wakabayashi W; Hasegawa S; Iwata M; Suzuki T; Maezawa M; Nakao S; Liao J; Iguchi K; Nakamura M
    BMC Complement Med Ther; 2024 Mar; 24(1):121. PubMed ID: 38486172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eliciting adverse effects data from participants in clinical trials.
    Allen EN; Chandler CI; Mandimika N; Leisegang C; Barnes K
    Cochrane Database Syst Rev; 2018 Jan; 1(1):MR000039. PubMed ID: 29372930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting.
    Iwasa E; Fujiyoshi Y; Kubota Y; Kimura R; Chandler RE; Taavola H; Norén GN; Wakao R
    Drug Saf; 2020 Nov; 43(11):1121-1131. PubMed ID: 32617874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
    Robert C; Hwu WJ; Hamid O; Ribas A; Weber JS; Daud AI; Hodi FS; Wolchok JD; Mitchell TC; Hersey P; Dronca R; Joseph RW; Boutros C; Min L; Long GV; Schachter J; Puzanov I; Dummer R; Lin J; Ibrahim N; Diede SJ; Carlino MS; Joshua AM
    Eur J Cancer; 2021 Feb; 144():182-191. PubMed ID: 33360855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
    Sato K; Mano T; Iwata A; Toda T
    J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
    Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø
    Ann Oncol; 2016 Jul; 27(7):1291-8. PubMed ID: 27117531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
    Ji HH; Tang XW; Dong Z; Song L; Jia YT
    Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
    Nishiyama H; Tanaka Y; Hamada M; Ozaki M; Minegishi T; Ito Y; Maekawa S; Yamamoto N
    BMC Cancer; 2023 Jun; 23(1):565. PubMed ID: 37340317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
    Aagaard L; Hallgreen CE; Hansen EH
    Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.
    Nawa H; Niimura T; Yagi K; Goda M; Zamami Y; Ishizawa K
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1402. PubMed ID: 33939324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016.
    Ha D; Choi SR; Kwon Y; Park HH; Shin JY
    Medicine (Baltimore); 2019 Aug; 98(33):e16785. PubMed ID: 31415382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
    Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
    Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.